In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
William D. Tap, MD
Advertisement
Articles by William D. Tap, MD
Advertisement
Latest Updated Articles
Drug Shows 10-Month Survival Improvement in SarcomaJune 7th 2015
Advertisement
Advertisement
Trending on CancerNetwork
1
The Impact of GLP-1–Mediated Weight Loss on Mammographic Density and Radiomic Risk
2
What Does the Future Hold for Bispecific Antibodies in Multiple Myeloma?
3
Exploring Upfront Cytoreductive Radiotherapy in Advanced RCC
4
Rusfertide May Become Part of Polycythemia Vera Armamentarium
5